Table 1 Patient characteristics at baseline.
(N, % of total cohort) | Total | Hip | Knee | |||
|---|---|---|---|---|---|---|
Total cohort | 809 | (100.0%) | 420 | (51.92%) | 389 | 48.08%) |
Sex female | 504 | (62.3%) | 221 | (52.6%) | 283 | (72.8%) |
Age (years; N = 809; Median, Q1-Q3) | 65 | (58–70) | 62 | (55–68) | 67 | (63–71) |
25–<60 y | 236 | (29.2%) | 182 | (43.3%) | 54 | (13.9%) |
60–<70 y | 351 | (43.4%) | 153 | (36.4%) | 198 | (50.9%) |
70–75 y | 222 | (27.4%) | 85 | (20.2%) | 137 | (35.2%) |
Smoking: Former smoker | 238 | (29.4%) | 141 | (33.6%) | 97 | (24.9%) |
Current smoker | 102 | (12.6%) | 70 | (16.7%) | 32 | (8.2%) |
BMI (kg/m²; N = 809; Median, Q1-Q3) | 27.9 | (25.5–30.9) | 26.8 | (24.5–29.5) | 29.2 | (26.5–32.1) |
<25 kg/m² | 181 | (22.4%) | 126 | (30.0%) | 55 | (14.1%) |
25–<30 kg/m² | 375 | (46.4%) | 200 | (47.6%) | 175 | (45.0%) |
30–<35 kg/m² | 200 | (24.7%) | 76 | (18.1%) | 124 | (31.9%) |
>=35 kg/m² | 53 | (6.6%) | 18 | (4.3%) | 35 | (9.0%) |
History of overweight/obesity | 466 | (57.6%) | 191 | (45.5%) | 275 | (70.7%) |
Diabetes mellitus type 2 | 70 | (8.7%) | 28 | (6.7%) | 42 | (10.8%) |
Gout | 100 | (12.4%) | 43 | (10.2%) | 57 | (14.7%) |
Hypertension | 415 | (51.3%) | 190 | (45.2%) | 225 | (57.8%) |
Cardiac infarction | 34 | (4.2%) | 18 | (4.3%) | 16 | (4.1%) |
Cardiac insufficiency | 153 | (18.9%) | 57 | (13.6%) | 96 | (24.7%) |
Hypercholesterolemia | 259 | (32.0%) | 127 | (30.2%) | 132 | (33.9%) |
Unknown | 123 | (15.2%) | 64 | (15.2%) | 59 | (15.2%) |
Cholesterol (mmol/l; N = 683; Median, Q1-Q3) | 5.7 | (5.1–6.4) | 5.6 | (5.0–6.3) | 5.8 | (5.2–6.4) |
Uric acid (mmol/l; N = 699; Median, Q1-Q3) | 315.4 | (265.0–376.0) | 315.4 | (267.8–376.0) | 313.5 | (257.5–375.5) |
hs-CRP (mg/l; N = 770; Median, Q1-Q3) | 2.52 | (1.22–4.97) | 2.59 | (1.19–4.96) | 2.47 | (1.26–5.00) |
Bilateral OA | 622 | (76.9%) | 330 | (78.6%) | 292 | (75.1%) |
Unilateral OA | 114 | (14.1%) | 72 | (17.1%) | 42 | (10.8%) |
Unknown | 73 | (9.0%) | 18 | (4.3%) | 55 | (14.1%) |
Generalized OA | 171 | (21.1%) | 64 | (15.2%) | 107 | (27.5%) |
Not-generalized OA | 468 | (57.8%) | 268 | (63.8%) | 200 | (51.4%) |
Unknown | 170 | (21.0%) | 88 | (21.0%) | 82 | (21.1%) |
Secondary OA | 296 | (36.6%) | 170 | (40.5%) | 126 | (32.4%) |
Primary OA | 489 | (60.4%) | 238 | (56.7%) | 251 | (64.5%) |
Unknown | 24 | (3.0%) | 12 | (2.9%) | 12 | (3.1%) |
20 years follow-up | ||||||
Deceased (N,%) | 407 | (50.3%) | 170 | (40.5%) | 237 | (60.9%) |
Observation time (years; Median, Q1-Q3) | 18.4 | (11.4–19.2) | 18.6 | (12.3–19.3) | 16.7 | (11.1–19.1) |
